## Rudolf Uher

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3831220/publications.pdf

Version: 2024-02-01

314 papers 27,719 citations

80 h-index 7333 152 g-index

392 all docs

392 docs citations

times ranked

392

29016 citing authors

#	Article	IF	Citations
1	Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nature Genetics, 2018, 50, 668-681.	9.4	2,224
2	Genetic Sensitivity to the Environment: The Case of the Serotonin Transporter Gene and Its Implications for Studying Complex Diseases and Traits. American Journal of Psychiatry, 2010, 167, 509-527.	4.0	1,260
3	Childhood Maltreatment Predicts Unfavorable Course of Illness and Treatment Outcome in Depression: A Meta-Analysis. American Journal of Psychiatry, 2012, 169, 141-151.	4.0	1,103
4	A mega-analysis of genome-wide association studies for major depressive disorder. Molecular Psychiatry, 2013, 18, 497-511.	4.1	1,002
5	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. Canadian Journal of Psychiatry, 2016, 61, 540-560.	0.9	746
6	Risk of Mental Illness in Offspring of Parents With Schizophrenia, Bipolar Disorder, and Major Depressive Disorder: A Meta-Analysis of Family High-Risk Studies. Schizophrenia Bulletin, 2014, 40, 28-38.	2.3	544
7	Rare and low-frequency coding variants alter human adult height. Nature, 2017, 542, 186-190.	13.7	544
8	Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. Journal of Psychopharmacology, 2015, 29, 459-525.	2.0	528
9	The moderation by the serotonin transporter gene of environmental adversity in the aetiology of mental illness: review and methodological analysis. Molecular Psychiatry, 2008, 13, 131-146.	4.1	455
10	Medial Prefrontal Cortex Activity Associated With Symptom Provocation in Eating Disorders. American Journal of Psychiatry, 2004, 161, 1238-1246.	4.0	421
11	Assessment of Bidirectional Relationships Between Physical Activity and Depression Among Adults. JAMA Psychiatry, 2019, 76, 399.	6.0	399
12	The moderation by the serotonin transporter gene of environmental adversity in the etiology of depression: 2009 update. Molecular Psychiatry, 2010, 15, 18-22.	4.1	373
13	Candidate Genes Expression Profile Associated with Antidepressants Response in the GENDEP Study: Differentiating between Baseline †Predictors' and Longitudinal †Targets'. Neuropsychopharmacology, 2013, 38, 377-385.	2.8	372
14	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. Canadian Journal of Psychiatry, 2016, 61, 524-539.	0.9	340
15	An Inflammatory Biomarker as a Differential Predictor of Outcome of Depression Treatment With Escitalopram and Nortriptyline. American Journal of Psychiatry, 2014, 171, 1278-1286.	4.0	336
16	Genome-Wide Pharmacogenetics of Antidepressant Response in the GENDEP Project. American Journal of Psychiatry, 2010, 167, 555-564.	4.0	314
17	Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms. Psychological Medicine, 2012, 42, 967-980.	2.7	298
18	Time for united action on depression: a Lancet–World Psychiatric Association Commission. Lancet, The, 2022, 399, 957-1022.	6.3	292

#	Article	IF	Citations
19	Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity. Nature Genetics, 2018, 50, 26-41.	9.4	286
20	Fecundity of Patients With Schizophrenia, Autism, Bipolar Disorder, Depression, Anorexia Nervosa, or Substance Abuse vs Their Unaffected Siblings. JAMA Psychiatry, 2013, 70, 22.	6.0	284
21	Role for the kinase SGK1 in stress, depression, and glucocorticoid effects on hippocampal neurogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 8708-8713.	3.3	272
22	Protective Effect of CRHR1 Gene Variants on the Development of Adult Depression Following Childhood Maltreatment. Archives of General Psychiatry, 2009, 66, 978.	13.8	260
23	MAJOR DEPRESSIVE DISORDER IN DSM-5: IMPLICATIONS FOR CLINICAL PRACTICE AND RESEARCH OF CHANGES FROM DSM-IV. Depression and Anxiety, 2014, 31, 459-471.	2.0	260
24	The contribution of prenatal and postnatal maternal anxiety and depression to child maladjustment. Depression and Anxiety, 2011, 28, 696-702.	2.0	234
25	Interaction between stress and the BDNFVal66Met polymorphism in depression: a systematic review and meta-analysis. BMC Medicine, 2014, 12, 7.	2.3	228
26	Measuring depression: comparison and integration of three scales in the GENDEP study. Psychological Medicine, 2008, 38, 289-300.	2.7	227
27	Functional Neuroanatomy of Body Shape Perception in Healthy and Eating-Disordered Women. Biological Psychiatry, 2005, 58, 990-997.	0.7	225
28	Cerebral processing of food-related stimuli: Effects of fasting and gender. Behavioural Brain Research, 2006, 169, 111-119.	1.2	223
29	Genome-Wide Association Study of Major Recurrent Depression in the U.K. Population. American Journal of Psychiatry, 2010, 167, 949-957.	4.0	221
30	Common Genetic Variation and Antidepressant Efficacy in Major Depressive Disorder: A Meta-Analysis of Three Genome-Wide Pharmacogenetic Studies. American Journal of Psychiatry, 2013, 170, 207-217.	4.0	216
31	Minimal phenotyping yields genome-wide association signals of low specificity for major depression. Nature Genetics, 2020, 52, 437-447.	9.4	207
32	Adverse reactions to antidepressants. British Journal of Psychiatry, 2009, 195, 202-210.	1.7	205
33	Geneââ,¬â€œEnvironment Interactions in Severe Mental Illness. Frontiers in Psychiatry, 2014, 5, 48.	1.3	204
34	Recovery and chronicity in anorexia nervosa. Biological Psychiatry, 2003, 54, 934-942.	0.7	203
35	Association between C-reactive protein (CRP) with depression symptom severity and specific depressive symptoms in major depression. Brain, Behavior, and Immunity, 2017, 62, 344-350.	2.0	202
36	Etiology in psychiatry: embracing the reality of polyâ€geneâ€environmental causation of mental illness. World Psychiatry, 2017, 16, 121-129.	4.8	202

#	Article	IF	CITATIONS
37	Contribution of Common Genetic Variants to Antidepressant Response. Biological Psychiatry, 2013, 73, 679-682.	0.7	199
38	The role of genetic variation in the causation of mental illness: an evolution-informed framework. Molecular Psychiatry, 2009, 14, 1072-1082.	4.1	192
39	Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics Journal, 2009, 9, 225-233.	0.9	188
40	Differential Neural Responses to Food Images in Women with Bulimia versus Anorexia Nervosa. PLoS ONE, 2011, 6, e22259.	1.1	187
41	SELF-REPORT AND CLINICIAN-RATED MEASURES OF DEPRESSION SEVERITY: CAN ONE REPLACE THE OTHER?. Depression and Anxiety, 2012, 29, 1043-1049.	2.0	182
42	The Impact of Phenotypic and Genetic Heterogeneity on Results of Genome Wide Association Studies of Complex Diseases. PLoS ONE, 2013, 8, e76295.	1,1	177
43	Polygenic interactions with environmental adversity in the aetiology of major depressive disorder. Psychological Medicine, 2016, 46, 759-770.	2.7	176
44	Genetic Association of Major Depression With Atypical Features and Obesity-Related Immunometabolic Dysregulations. JAMA Psychiatry, 2017, 74, 1214.	6.0	174
45	Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression. British Journal of Psychiatry, 2009, 194, 252-259.	1.7	170
46	Effect of Left Prefrontal Repetitive Transcranial Magnetic Stimulation on Food Craving. Biological Psychiatry, 2005, 58, 840-842.	0.7	156
47	Combining clinical variables to optimize prediction of antidepressant treatment outcomes. Journal of Psychiatric Research, 2016, 78, 94-102.	1.5	149
48	Repetitive Transcranial Magnetic Stimulation Reduces Cue-Induced Food Craving in Bulimic Disorders. Biological Psychiatry, 2010, 67, 793-795.	0.7	147
49	MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes. Nature Communications, 2017, 8, 15497.	5.8	144
50	Moderation of antidepressant response by the serotonin transporter gene. British Journal of Psychiatry, 2009, 195, 30-38.	1.7	143
51	Brain lesions and eating disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 852-857.	0.9	139
52	Serotonin transporter gene moderates childhood maltreatment's effects on persistent but not single-episode depression: Replications and implications for resolving inconsistent results. Journal of Affective Disorders, 2011, 135, 56-65.	2.0	136
53	Therapygenetics: the 5HTTLPR and response to psychological therapy. Molecular Psychiatry, 2012, 17, 236-237.	4.1	135
54	Relative impact of maternal depression and associated risk factors on offspring psychopathology. British Journal of Psychiatry, 2012, 200, 124-129.	1.7	134

#	Article	IF	CITATIONS
55	An investigation of decision making in anorexia nervosa using the Iowa Gambling Task and skin conductance measurements. Journal of the International Neuropsychological Society, 2007, 13, 635-41.	1.2	131
56	Differential motivational responses to food and pleasurable cues in anorexia and bulimia nervosa: a startle reflex paradigm. Psychological Medicine, 2006, 36, 1327-1335.	2.7	128
57	The implications of gene–environment interactions in depression: will cause inform cure?. Molecular Psychiatry, 2008, 13, 1070-1078.	4.1	128
58	Risk and protective factors for mental disorders beyond genetics: an evidenceâ€based atlas. World Psychiatry, 2021, 20, 417-436.	4.8	127
59	Association of Maternal Use of Folic Acid and Multivitamin Supplements in the Periods Before and During Pregnancy With the Risk of Autism Spectrum Disorder in Offspring. JAMA Psychiatry, 2018, 75, 176.	6.0	126
60	Classification of feeding and eating disorders: review of evidence and proposals for ICDâ€11. World Psychiatry, 2012, 11, 80-92.	4.8	125
61	Insulin resistance and outcome in bipolar disorder. British Journal of Psychiatry, 2015, 206, 52-57.	1.7	120
62	Neural correlates of body dissatisfaction in anorexia nervosa. Neuropsychologia, 2010, 48, 2878-2885.	0.7	118
63	Association Between Bipolar Spectrum Features and Treatment Outcomes in Outpatients With Major Depressive Disorder. Archives of General Psychiatry, 2010, 68, 351.	13.8	118
64	Brain Structural Signature of Familial Predisposition for Bipolar Disorder: Replicable Evidence For Involvement of the Right Inferior Frontal Gyrus. Biological Psychiatry, 2013, 73, 144-152.	0.7	118
65	Early and Delayed Onset of Response to Antidepressants in Individual Trajectories of Change During Treatment of Major Depression. Journal of Clinical Psychiatry, 2011, 72, 1478-1484.	1.1	117
66	Genome-wide gene-environment analyses of major depressive disorder and reported lifetime traumatic experiences in UK Biobank. Molecular Psychiatry, 2020, 25, 1430-1446.	4.1	116
67	Lifetime prevalence of anxiety disorders in people with bipolar disorder: a systematic review and meta-analysis. Lancet Psychiatry,the, 2015, 2, 710-717.	3.7	113
68	Genetic Predictors of Response to Serotonergic and Noradrenergic Antidepressants in Major Depressive Disorder: A Genome-Wide Analysis of Individual-Level Data and a Meta-Analysis. PLoS Medicine, 2012, 9, e1001326.	3.9	110
69	Eating disorders, gene–environment interactions and epigenetics. Neuroscience and Biobehavioral Reviews, 2011, 35, 784-793.	2.9	108
70	Trajectories of change in depression severity during treatment with antidepressants. Psychological Medicine, 2010, 40, 1367-1377.	2.7	107
71	Genetic Predictors of Increase in Suicidal Ideation During Antidepressant Treatment in the GENDEP Project. Neuropsychopharmacology, 2009, 34, 2517-2528.	2.8	105
72	Genetic Differences in the Immediate Transcriptome Response to Stress Predict Risk-Related Brain Function and Psychiatric Disorders. Neuron, 2015, 86, 1189-1202.	3.8	102

#	Article	IF	Citations
73	Absolute Measurements of Macrophage Migration Inhibitory Factor and Interleukin- $1$ - $\hat{l}^2$ mRNA Levels Accurately Predict Treatment Response in Depressed Patients. International Journal of Neuropsychopharmacology, 2016, 19, pyw045.	1.0	100
74	Neuroprotective effect of lithium on hippocampal volumes in bipolar disorder independent of long-term treatment response. Psychological Medicine, 2014, 44, 507-517.	2.7	99
75	Genetic relationships between suicide attempts, suicidal ideation and major psychiatric disorders: A genomeâ€wide association and polygenic scoring study. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2014, 165, 428-437.	1.1	99
76	Genomewide Association Scan of Suicidal Thoughts and Behaviour in Major Depression. PLoS ONE, 2011, 6, e20690.	1.1	98
77	Brain Age in Early Stages of Bipolar Disorders or Schizophrenia. Schizophrenia Bulletin, 2019, 45, 190-198.	2.3	94
78	Melancholic, atypical and anxious depression subtypes and outcome of treatment with escitalopram and nortriptyline. Journal of Affective Disorders, 2011, 132, 112-120.	2.0	93
79	Genome-wide association study of increasing suicidal ideation during antidepressant treatment in the GENDEP project. Pharmacogenomics Journal, 2012, 12, 68-77.	0.9	92
80	Body weight as a predictor of antidepressant efficacy in the GENDEP project. Journal of Affective Disorders, 2009, 118, 147-154.	2.0	89
81	Gene–environment interplay in the etiology of psychosis. Psychological Medicine, 2018, 48, 1925-1936.	2.7	89
82	The Genetic Architecture of Depression in Individuals of East Asian Ancestry. JAMA Psychiatry, 2021, 78, 1258.	6.0	88
83	Does Childhood Trauma Moderate Polygenic Risk for Depression? A Meta-analysis of 5765 Subjects From the Psychiatric Genomics Consortium. Biological Psychiatry, 2018, 84, 138-147.	0.7	87
84	An Analysis of Two Genome-wide Association Meta-analyses Identifies a New Locus for Broad Depression Phenotype. Biological Psychiatry, 2017, 82, 322-329.	0.7	84
85	Gene–Environment Interaction in Major Depression and Antidepressant Treatment Response. Current Psychiatry Reports, 2012, 14, 129-137.	2.1	82
86	Obesity, dyslipidemia and brain age in first-episode psychosis. Journal of Psychiatric Research, 2018, 99, 151-158.	1.5	80
87	Thinking about Eating Food Activates Visual Cortex with Reduced Bilateral Cerebellar Activation in Females with Anorexia Nervosa: An fMRI Study. PLoS ONE, 2012, 7, e34000.	1.1	80
88	Genes, Environment, and Individual Differences in Responding to Treatment for Depression. Harvard Review of Psychiatry, 2011, 19, 109-124.	0.9	78
89	Elevated pain threshold in eating disorders: physiological and psychological factors. Journal of Psychiatric Research, 2005, 39, 431-438.	1.5	75
90	Genetic differences in cytochrome P450 enzymes and antidepressant treatment response. Journal of Psychopharmacology, 2014, 28, 133-141.	2.0	75

#	Article	IF	CITATIONS
91	A familial risk enriched cohort as a platform for testing early interventions to prevent severe mental illness. BMC Psychiatry, 2014, 14, 344.	1.1	74
92	Gene–environment interactions in common mental disorders: an update and strategy for a genome-wide search. Social Psychiatry and Psychiatric Epidemiology, 2014, 49, 3-14.	1.6	74
93	Evidence of causal effect of major depression on alcohol dependence: findings from the psychiatric genomics consortium. Psychological Medicine, 2019, 49, 1218-1226.	2.7	74
94	Depressive disorder moderates the effect of the FTO gene on body mass index. Molecular Psychiatry, 2012, 17, 604-611.	4.1	72
95	DNA methylation in interleukin-11 predicts clinical response to antidepressants in GENDEP. Translational Psychiatry, 2013, 3, e300-e300.	2.4	71
96	Pharmacogenetics of antidepressant response: A polygenic approach. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 75, 128-134.	2.5	71
97	Interaction between serotonin transporter gene variants and life events predicts response to antidepressants in the GENDEP project. Pharmacogenomics Journal, 2011, 11, 138-145.	0.9	70
98	l'm not as slim as that girl: Neural bases of body shape self-comparison to media images. NeuroImage, 2007, 37, 674-681.	2.1	69
99	<i>CYP2C19</i> genotype predicts steady state escitalopram concentration in GENDEP. Journal of Psychopharmacology, 2012, 26, 398-407.	2.0	69
100	Stressful life events and the brain-derived neurotrophic factor gene in bipolar disorder. Journal of Affective Disorders, 2010, 125, 345-349.	2.0	68
101	Tumor necrosis factor and its targets in the inflammatory cytokine pathway are identified as putative transcriptomic biomarkers for escitalopram response. European Neuropsychopharmacology, 2013, 23, 1105-1114.	0.3	68
102	Insulin Resistance, Diabetes Mellitus, and Brain Structure in Bipolar Disorders. Neuropsychopharmacology, 2014, 39, 2910-2918.	2.8	67
103	CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ, The, 2021, 373, n857.	3.0	65
104	Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: Meta-analysis of data from genome-wide association studies. European Neuropsychopharmacology, 2018, 28, 945-954.	0.3	64
105	An examination of decision making in bulimia nervosa. Journal of Clinical and Experimental Neuropsychology, 2009, 31, 455-461.	0.8	63
106	Sex-Dependent Shared and Nonshared Genetic Architecture Across Mood and Psychotic Disorders. Biological Psychiatry, 2022, 91, 102-117.	0.7	61
107	Symptomatic and Functional Outcomes and Early Prediction of Response to Escitalopram Monotherapy and Sequential Adjunctive Aripiprazole Therapy in Patients With Major Depressive Disorder. Journal of Clinical Psychiatry, 2019, 80, .	1.1	61
108	The association between lower educational attainment and depression owing to shared genetic effects? Results in ~25 000 subjects. Molecular Psychiatry, 2015, 20, 735-743.	4.1	59

#	Article	IF	CITATIONS
109	Personality Pathology Among Individuals With a Lifetime History of Anorexia Nervosa. Journal of Personality Disorders, 2006, 20, 417-430.	0.8	58
110	Prospective Association between Childhood Behavioral Inhibition and Anxiety: a Meta-Analysis. Research on Child and Adolescent Psychopathology, 2020, 48, 57-66.	1.4	57
111	A genetic risk score combining 32 SNPs is associated with body mass index and improves obesity prediction in people with major depressive disorder. BMC Medicine, 2015, 13, 86.	2.3	56
112	The genetics of affective disorder and suicide. European Psychiatry, 2010, 25, 275-277.	0.1	55
113	SEROTONIN TRANSPORTER LENGTH POLYMORPHISM, CHILDHOOD MALTREATMENT, AND CHRONIC DEPRESSION: A SPECIFIC GENE-ENVIRONMENT INTERACTION. Depression and Anxiety, 2013, 30, 5-13.	2.0	55
114	Integrative mouse and human mRNA studies using WGCNA nominates novel candidate genes involved in the pathogenesis of major depressive disorder. Pharmacogenomics, 2013, 14, 1979-1990.	0.6	55
115	Basing psychiatric classification on scientific foundation: Problems and prospects. International Review of Psychiatry, 2012, 24, 591-605.	1.4	54
116	Self-, parent-report and interview measures of obsessive–compulsive disorder in children and adolescents. Journal of Anxiety Disorders, 2008, 22, 979-990.	1.5	52
117	A genome-wide association study of a sustained pattern of antidepressant response. Journal of Psychiatric Research, 2013, 47, 1157-1165.	1.5	52
118	The endogenous and reactive depression subtypes revisited: integrative animal and human studies implicate multiple distinct molecular mechanisms underlying major depressive disorder. BMC Medicine, 2014, 12, 73.	2.3	52
119	Revision of ICD $\hat{a} \in \hat{a}$ status update on feeding and eating disorders. Advances in Eating Disorders (Abingdon, England ), 2013, 1, 10-20.	0.8	51
120	Autism risk following antidepressant medication during pregnancy. Psychological Medicine, 2017, 47, 2787-2796.	2.7	51
121	Antidepressant drug-specific prediction of depression treatment outcomes from genetic and clinical variables. Scientific Reports, 2018, 8, 5530.	1.6	51
122	Treatment response classes in major depressive disorder identified by model-based clustering and validated by clinical prediction models. Translational Psychiatry, 2019, 9, 187.	2.4	51
123	Hair Cortisol in Twins: Heritability and Genetic Overlap with Psychological Variables and Stress-System Genes. Scientific Reports, 2017, 7, 15351.	1.6	50
124	Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample. Pharmacogenomics, 2011, 12, 365-377.	0.6	49
125	Interaction between the <i>FTO</i> gene, body mass index and depression: meta-analysis of 13701 individuals. British Journal of Psychiatry, 2017, 211, 70-76.	1.7	49
126	Brain age in bipolar disorders: Effects of lithium treatment. Australian and New Zealand Journal of Psychiatry, 2019, 53, 1179-1188.	1.3	49

#	Article	IF	CITATIONS
127	Offspring of parents with schizophrenia, bipolar disorder, and depression. Psychiatric Genetics, 2019, 29, 160-169.	0.6	49
128	Use of Machine Learning for Predicting Escitalopram Treatment Outcome From Electroencephalography Recordings in Adult Patients With Depression. JAMA Network Open, 2020, 3, e1918377.	2.8	49
129	Screening young people for obsessive-compulsive disorder. British Journal of Psychiatry, 2007, 191, 353-354.	1.7	48
130	Estimating the heritability of reporting stressful life events captured by common genetic variants. Psychological Medicine, 2013, 43, 1965-1971.	2.7	46
131	Genetic Sensitivity to the Environment: The Case of the Serotonin Transporter Gene and Its Implications for Studying Complex Diseases and Traits. Focus (American Psychiatric Publishing), 2010, 8, 398-416.	0.4	45
132	Genome-wide association analysis of copy number variation in recurrent depressive disorder. Molecular Psychiatry, 2013, 18, 183-189.	4.1	45
133	Psychosis Polyrisk Score (PPS) for the Detection of Individuals At-Risk and the Prediction of Their Outcomes. Frontiers in Psychiatry, 2019, 10, 174.	1.3	45
134	Genome-wide association study of antidepressant treatment resistance in a population-based cohort using health service prescription data and meta-analysis with GENDEP. Pharmacogenomics Journal, 2020, 20, 329-341.	0.9	45
135	The truth about genetic variation in the serotonin transporter gene and response to stress and medication. British Journal of Psychiatry, 2011, 198, 424-427.	1.7	44
136	Variation in GNB3 predicts response and adverse reactions to antidepressants. Journal of Psychopharmacology, 2011, 25, 867-874.	2.0	44
137	Biomarkers predicting treatment outcome in depression: what is clinically significant?. Pharmacogenomics, 2012, 13, 233-240.	0.6	44
138	Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samples. British Journal of Psychiatry, 2019, 214, 36-41.	1.7	44
139	Suicidal ideation during treatment of depression with escitalopram and nortriptyline in Genome-Based Therapeutic Drugs for Depression (GENDEP): a clinical trial. BMC Medicine, 2009, 7, 60.	2.3	43
140	Poor Decision Making in Male Patients with Anorexia Nervosa. European Eating Disorders Review, 2012, 20, 169-173.	2.3	43
141	Neurotrophic factors in depression in response to treatment. Journal of Affective Disorders, 2015, 183, 287-294.	2.0	43
142	Changes in body weight during pharmacological treatment of depression. International Journal of Neuropsychopharmacology, 2011, 14, 367-375.	1.0	41
143	New insights into the pharmacogenomics of antidepressant response from the GENDEP and STAR*D studies: rare variant analysis and high-density imputation. Pharmacogenomics Journal, 2018, 18, 413-421.	0.9	40
144	Interaction between specific forms of childhood maltreatment and the serotonin transporter gene (5-HTT) in recurrent depressive disorder. Journal of Affective Disorders, 2013, 145, 136-141.	2.0	39

#	Article	IF	CITATIONS
145	Prevalence of current anxiety disorders in people with bipolar disorder during euthymia: a meta-analysis. Psychological Medicine, 2017, 47, 1107-1115.	2.7	39
146	Machine learning in the prediction of depression treatment outcomes: a systematic review and meta-analysis. Psychological Medicine, 2021, 51, 2742-2751.	2.7	38
147	Predictors of Response and Drop-Out During Intensive Dialectical Behavior Therapy. Journal of Personality Disorders, 2010, 24, 634-650.	0.8	37
148	FUNCTIONAL POLYMORPHISM IN THE BRAIN-DERIVED NEUROTROPHIC FACTOR GENE INTERACTS WITH STRESSFUL LIFE EVENTS BUT NOT CHILDHOOD MALTREATMENT IN THE ETIOLOGY OF DEPRESSION. Depression and Anxiety, 2014, 31, 326-334.	2.0	37
149	Polygenic risk scores for major depressive disorder and neuroticism as predictors of antidepressant response: Meta-analysis of three treatment cohorts. PLoS ONE, 2018, 13, e0203896.	1.1	37
150	Subliminal food images compromise superior working memory performance in women with restricting anorexia nervosa. Consciousness and Cognition, 2012, 21, 751-763.	0.8	35
151	The Effect of Parental Modeling on Child Pain Responses: The Role of Parent and Child Sex. Journal of Pain, 2017, 18, 702-715.	0.7	35
152	Association of Antidepressant Medication Use During Pregnancy With Intellectual Disability in Offspring. JAMA Psychiatry, 2017, 74, 1031.	6.0	34
153	Cognitive Performance in First-Degree Relatives of Individuals With vs Without Major Depressive Disorder. JAMA Psychiatry, 2019, 76, 297.	6.0	34
154	Trends in hospital admissions for eating disorders in a country undergoing a socio-cultural transition, the Czech Republic 1981–2005. Social Psychiatry and Psychiatric Epidemiology, 2010, 45, 541-550.	1.6	33
155	Childhood maltreatment and comorbid anxiety in people with bipolar disorder. Journal of Affective Disorders, 2016, 192, 22-27.	2.0	33
156	Integrated genome-wide methylation and expression analyses reveal functional predictors of response to antidepressants. Translational Psychiatry, 2019, 9, 254.	2.4	33
157	A polygenic predictor of treatment-resistant depression using whole exome sequencing and genome-wide genotyping. Translational Psychiatry, 2020, 10, 50.	2.4	33
158	The inability to ignore: distractibility in women with restricting anorexia nervosa. Psychological Medicine, 2008, 38, 1741-1748.	2.7	32
159	Stressful life events, cognitive symptoms of depression and response to antidepressants in GENDEP. Journal of Affective Disorders, 2010, 127, 337-342.	2.0	32
160	Reactivity of affect and self-esteem during remission in bipolar affective disorder: An experimental investigation. Journal of Affective Disorders, 2011, 134, 102-111.	2.0	32
161	The role of loss and danger events in symptom exacerbation in bipolar disorder. Journal of Psychiatric Research, 2012, 46, 1584-1589.	1.5	32
162	Resistance to antidepressant treatment is associated with polymorphisms in the leptin gene, decreased leptin mRNA expression, and decreased leptin serum levels. European Neuropsychopharmacology, 2013, 23, 653-662.	0.3	32

#	Article	IF	CITATIONS
163	Attention-deficit hyperactivity disorder and anxiety disorders as precursors of bipolar disorder onset in adulthood. British Journal of Psychiatry, 2018, 213, 555-560.	1.7	32
164	The Everyday Feeling Questionnaire: the structure and validation of a measure of general psychological well-being and distress. Social Psychiatry and Psychiatric Epidemiology, 2010, 45, 413-423.	1.6	31
165	Sexual dysfunction during treatment with serotonergic and noradrenergic antidepressants: Clinical description and the role of the <i>5-HTTLPR </i> World Journal of Biological Psychiatry, 2011, 12, 528-538.	1.3	31
166	Dissecting the Genetic Heterogeneity of Depression Through Age at Onset. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2012, 159B, 859-868.	1.1	31
167	Whole-exome sequencing identifies a polymorphism in the BMP5 gene associated with SSRI treatment response in major depression. Journal of Psychopharmacology, 2013, 27, 915-920.	2.0	31
168	Exploring the role of drug-metabolising enzymes in antidepressant side effects. Psychopharmacology, 2015, 232, 2609-2617.	1.5	31
169	Interaction between childhood maltreatment on immunogenetic risk in depression: Discovery and replication in clinical case-control samples. Brain, Behavior, and Immunity, 2018, 67, 203-210.	2.0	31
170	Prevalence of attentionâ€deficit/hyperactivity disorder in people with mood disorders: A systematic review and metaâ€analysis. Acta Psychiatrica Scandinavica, 2021, 143, 380-391.	2.2	31
171	Convergent Animal and Human Evidence Suggests a Role of PPM1A Gene in Response to Antidepressants. Biological Psychiatry, 2011, 69, 360-365.	0.7	30
172	Non-steroidal anti-inflammatory drugs and efficacy of antidepressants in major depressive disorder. Psychological Medicine, 2012, 42, 2027-2035.	2.7	30
173	Brain responses to body image stimuli but not food are altered in women with bulimia nervosa. BMC Psychiatry, 2013, 13, 302.	1.1	28
174	Protocol for the development of a CONSORT extension for RCTs using cohorts and routinely collected health data. Research Integrity and Peer Review, 2018, 3, 9.	2.2	28
175	Antidepressant-dependent mRNA changes in mouse associated with hippocampal neurogenesis in a mouse model of depression. Pharmacogenetics and Genomics, 2012, 22, 765-776.	0.7	28
176	Antidepressants, social adversity and outcome of depression in general practice. Journal of Affective Disorders, 2010, 121, 239-246.	2.0	27
177	Classification issues and challenges in child and adolescent psychopathology. International Review of Psychiatry, 2012, 24, 514-529.	1.4	27
178	Interaction between the BDNF gene Val/66/Met polymorphism and morning cortisol levels as a predictor of depression in adult women. British Journal of Psychiatry, 2012, 201, 313-319.	1.7	27
179	Classical Human Leukocyte Antigen Alleles and C4 Haplotypes Are Not Significantly Associated With Depression. Biological Psychiatry, 2020, 87, 419-430.	0.7	27
180	Genome-wide Burden of Rare Short Deletions Is Enriched in Major Depressive Disorder in Four Cohorts. Biological Psychiatry, 2019, 85, 1065-1073.	0.7	25

#	Article	IF	CITATIONS
181	Investigation of blood mRNA biomarkers for suicidality in an independent sample. Translational Psychiatry, 2014, 4, e474-e474.	2.4	24
182	Neurodevelopmental and genetic determinants of exposure to adversity among youth at risk for mental illness. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2020, 61, 536-544.	3.1	24
183	Clinical, behavioral, and neural measures of reward processing correlate with escitalopram response in depression: a Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report. Neuropsychopharmacology, 2020, 45, 1390-1397.	2.8	23
184	Stressful life events and the serotonin transporter gene (5-HTT) in recurrent clinical depression. Journal of Affective Disorders, 2012, 136, 189-193.	2.0	22
185	Early change in reward and punishment sensitivity as a predictor of response to antidepressant treatment for major depressive disorder: a CAN-BIND-1 report. Psychological Medicine, 2019, 49, 1629-1638.	2.7	22
186	The interaction between child maltreatment, adult stressful life events and the 5-HTTLPR in major depression. Journal of Psychiatric Research, 2013, 47, 1032-1035.	1.5	21
187	Familiality and SNP heritability of age at onset and episodicity in major depressive disorder. Psychological Medicine, 2015, 45, 2215-2225.	2.7	21
188	Stimulant Medication and Psychotic Symptoms in Offspring of Parents With Mental Illness. Pediatrics, 2016, 137, .	1.0	21
189	Phenotypic Association Analyses With Copy Number Variation in Recurrent Depressive Disorder. Biological Psychiatry, 2016, 79, 329-336.	0.7	21
190	Hot and cold executive functions in youth with psychotic symptoms. Psychological Medicine, 2017, 47, 2844-2853.	2.7	21
191	Observed psychopathology in offspring of parents with major depressive disorder, bipolar disorder and schizophrenia. Psychological Medicine, 2020, 50, 1050-1056.	2.7	21
192	ATP-binding cassette sub-family F member 1 (ABCF1) is identified as a putative therapeutic target of escitalopram in the inflammatory cytokine pathway. Journal of Psychopharmacology, 2013, 27, 609-615.	2.0	20
193	Copy number variants and therapeutic response to antidepressant medication in major depressive disorder. Pharmacogenomics Journal, 2014, 14, 395-399.	0.9	20
194	Larger right inferior frontal gyrus volume and surface area in participants at genetic risk for bipolar disorders. Psychological Medicine, 2019, 49, 1308-1315.	2.7	20
195	Gene-Environment Interaction: Overcoming Methodological Challenges. Novartis Foundation Symposium, 2008, 293, 13-30.	1.2	20
196	Transcriptomics and the mechanisms of antidepressant efficacy. European Neuropsychopharmacology, 2016, 26, 105-112.	0.3	19
197	Genes associated with anhedonia: a new analysis in a large clinical trial (GENDEP). Translational Psychiatry, 2018, 8, 150.	2.4	19
198	Cognitive-behavioural interventions for prevention and treatment of anxiety in young children: A systematic review and meta-analysis. Clinical Psychology Review, 2020, 81, 101904.	6.0	19

#	Article	IF	CITATIONS
199	Role of Polygenic Risk Score in the Familial Transmission of Bipolar Disorder in Youth. JAMA Psychiatry, 2022, 79, 160.	6.0	19
200	History of suicide attempts among patients with depression in the GENDEP project. Journal of Affective Disorders, 2010, 123, 131-137.	2.0	18
201	Pharmacoproteomic investigation into antidepressant response in two mouse inbred strains. Proteomics, 2012, 12, 2355-2365.	1.3	18
202	Genetic predictors of antidepressant side effects: A grouped candidate gene approach in the Genome-Based Therapeutic Drugs for Depression (GENDEP) study. Journal of Psychopharmacology, 2014, 28, 142-150.	2.0	18
203	Long-term effects of depression treatment. Lancet Psychiatry, the, 2016, 3, 95-96.	3.7	18
204	Genetic disposition to inflammation and response to antidepressants in major depressive disorder. Journal of Psychiatric Research, 2018, 105, 17-22.	1.5	18
205	Polygenic risk for circulating reproductive hormone levels and their influence on hippocampal volume and depression susceptibility. Psychoneuroendocrinology, 2019, 106, 284-292.	1.3	18
206	Stability of symptoms across major depressive episodes in bipolar disorder. Bipolar Disorders, 2009, 11, 867-875.	1.1	17
207	Genome-wide association study of co-occurring anxiety in major depression. World Journal of Biological Psychiatry, 2013, 14, 611-621.	1.3	17
208	Functional neuroanatomy of body checking in people with anorexia nervosa. International Journal of Eating Disorders, 2013, 46, 653-662.	2.1	17
209	Childhood maltreatment and cognitive functioning in patients with major depressive disorder: a CAN-BIND-1 report. Psychological Medicine, 2020, 50, 2536-2547.	2.7	17
210	A Nationwide Cohort Study of Nonrandom Mating in Schizophrenia and Bipolar Disorder. Schizophrenia Bulletin, 2021, 47, 1342-1350.	2.3	17
211	Increasing Cognitive Load Reduces Interference from Masked Appetitive and Aversive but Not Neutral Stimuli. PLoS ONE, 2014, 9, e94417.	1.1	17
212	Genome-wide approaches to antidepressant treatment: working towards understanding and predicting response. Genome Medicine, 2012, 4, 52.	3.6	16
213	Genomeâ€wide association analysis accounting for environmental factors through propensityâ€score matching: Application to stressful live events in major depressive disorder. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2013, 162, 521-529.	1.1	16
214	Genetic susceptibility for bipolar disorder and response to antidepressants in major depressive disorder. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2014, 165, 77-83.	1.1	16
215	The genomeâ€wide expression effects of escitalopram and its relationship to neurogenesis, hippocampal volume, and antidepressant response. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2017, 174, 427-434.	1.1	16
216	Association of Whole-Genome and NETRIN1 Signaling Pathway–Derived Polygenic Risk Scores for Major Depressive Disorder and White Matter Microstructure in the UK Biobank. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2019, 4, 91-100.	1.1	16

#	Article	IF	CITATIONS
217	Exemplar scoring identifies genetically separable phenotypes of lithium responsive bipolar disorder. Translational Psychiatry, 2021, 11, 36.	2.4	16
218	Predicting Worsening Suicidal Ideation With Clinical Features and Peripheral Expression of Messenger RNA and MicroRNA During Antidepressant Treatment. Journal of Clinical Psychiatry, 2019, 80, .	1.1	16
219	Typology of clinical course in bipolar disorder based on 18-month naturalistic follow-up. Psychological Medicine, 2013, 43, 789-799.	2.7	15
220	NEUROTICISM MEDIATES THE EFFECT OF P2RX7 ON OUTCOMES OF MOOD DISORDERS. Depression and Anxiety, 2012, 29, 816-823.	2.0	14
221	Disruptive mood dysregulation disorder in offspring of parents with depression and bipolar disorder. British Journal of Psychiatry, 2017, 210, 408-412.	1.7	14
222	Anxiety disorders and childhood maltreatment as predictors of outcome in bipolar disorder. Journal of Affective Disorders, 2018, 225, 337-341.	2.0	14
223	Forum: the case for gene–environment interactions in psychiatry. Current Opinion in Psychiatry, 2008, 21, 318-321.	3.1	13
224	Sleep in Offspring of Parents With Mood Disorders. Frontiers in Psychiatry, 2019, 10, 225.	1.3	13
225	The Developmental Brain Age Is Associated With Adversity, Depression, and Functional Outcomes Among Adolescents. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2022, 7, 406-414.	1.1	13
226	It would not have happened to me at home: qualitative exploration of sojourns abroad and eating disorders in young Czech women. European Eating Disorders Review, 2008, 16, 207-214.	2.3	12
227	Non-random dropout and the relative efficacy of escitalopram and nortriptyline inÂtreating major depressive disorder. Journal of Psychiatric Research, 2012, 46, 1333-1338.	1.5	12
228	Genomics and the classification of mental illness: focus on broader categories. Genome Medicine, 2013, 5, 97.	3.6	12
229	Epigenetic traces of childhood maltreatment in peripheral blood: a new strategy to explore gene–environment interactions. British Journal of Psychiatry, 2014, 204, 3-5.	1.7	12
230	Childhood maltreatment and the medical morbidity in bipolar disorder: a case–control study. International Journal of Bipolar Disorders, 2017, 5, 30.	0.8	12
231	Assessment of Psychopathology. JAMA Psychiatry, 2020, 77, 557.	6.0	12
232	Provocation of Symmetry/Ordering Symptoms in Anorexia nervosa: A Functional Neuroimaging Study. PLoS ONE, 2014, 9, e97998.	1.1	11
233	Real-world digital implementation of the Psychosis Polyrisk Score (PPS): A pilot feasibility study. Schizophrenia Research, 2020, 226, 176-183.	1.1	11
234	Highly polygenic architecture of antidepressant treatment response: Comparative analysis of SSRI and NRI treatment in an animal model of depression. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2017, 174, 235-250.	1.1	10

#	Article	IF	CITATIONS
235	Protocol for a scoping review to support development of a CONSORT extension for randomised controlled trials using cohorts and routinely collected health data. BMJ Open, 2018, 8, e025266.	0.8	10
236	Basic symptoms in offspring of parents with mood and psychotic disorders. BJPsych Open, 2019, 5, e54.	0.3	10
237	Effect of antidepressant switching between nortriptyline and escitalopram after a failed first antidepressant treatment among patients with major depressive disorder. British Journal of Psychiatry, 2019, 215, 494-501.	1.7	10
238	Neuroanatomical Bases of Eating Disorders. , 0, , 1173-1179.		9
239	Like father like daughter: sex-specific parent-of-origin effects in the transmission of liability for psychotic symptoms to offspring. Journal of Developmental Origins of Health and Disease, 2019, 10, 100-107.	0.7	9
240	Affective lability in offspring of parents with major depressive disorder, bipolar disorder and schizophrenia. European Child and Adolescent Psychiatry, 2020, 29, 445-451.	2.8	9
241	Methods and results used in the development of a consensus-driven extension to the Consolidated Standards of Reporting Trials (CONSORT) statement for trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE). BMJ Open, 2021, 11, e049093.	0.8	9
242	Symptom Dimension of Interest-Activity Indicates Need for Aripiprazole Augmentation of Escitalopram in Major Depressive Disorder. Journal of Clinical Psychiatry, 2020, 81, .	1.1	9
243	Psychotic symptoms are associated with lower cortical folding in youth at risk for mental illness. Journal of Psychiatry and Neuroscience, 2020, 45, 125-133.	1.4	8
244	Hypothalamus volume and DNA methylation of stress axis genes in major depressive disorder: A CAN-BIND study report. Psychoneuroendocrinology, 2021, 132, 105348.	1.3	8
245	Reliability of multimodal MRI brain measures in youth at risk for mental illness. Brain and Behavior, 2020, 10, e01609.	1.0	8
246	Do Suicidal Thoughts or Behaviors Recur During a Second Antidepressant Treatment Trial?. Journal of Clinical Psychiatry, 2012, 73, 1439-1442.	1.1	8
247	Specific anxiety disorders and subsequent risk for bipolar disorder: a nationwide study. World Psychiatry, 2016, 15, 187-188.	4.8	7
248	Trajectories of Suicidal Ideation During 12 Weeks of Escitalopram or Nortriptyline Antidepressant Treatment Among 811 Patients With Major Depressive Disorder. Journal of Clinical Psychiatry, 2019, 80,	1.1	7
249	Attention-deficit/hyperactivity disorder and other neurodevelopmental disorders in offspring of parents with depression and bipolar disorder. Psychological Medicine, 2021, , 1-8.	2.7	7
250	Probing the Genome to Understand Suicide. American Journal of Psychiatry, 2010, 167, 1425-1427.	4.0	6
251	Why negative meta-analyses may be false?. European Neuropsychopharmacology, 2013, 23, 1307-1309.	0.3	6
252	Review of an innovative approach to practical trials: the †cohort multiple RCT' design. Trials, 2015, 16, .	0.7	6

#	Article	IF	Citations
253	Personâ€eentered measurementâ€based care for depression. World Psychiatry, 2016, 15, 238-239.	4.8	6
254	Clinical course predicts long-term outcomes in bipolar disorder. Psychological Medicine, 2019, 49, 1109-1117.	2.7	6
255	"One Degree of Separation― A Mixed-Methods Evaluation of Canadian Mental Health Care User and Provider Experiences With Remote Care During COVID-19. Canadian Journal of Psychiatry, 2022, , 070674372110706.	0.9	6
256	Sex-Specific Transmission of Anxiety Disorders From Parents to Offspring. JAMA Network Open, 2022, 5, e2220919.	2.8	6
257	Biomarkers of treatment outcome in schizophrenia: Defining a benchmark for clinical significance. European Neuropsychopharmacology, 2015, 25, 1578-1585.	0.3	5
258	Cognition in offspring of parents with psychotic and non-psychotic severe mental illness. Journal of Psychiatric Research, 2020, 130, 306-312.	1.5	5
259	Estimating Severity of Depression From Acoustic Features and Embeddings of Natural Speech., 2021,,.		5
260	Transcriptome-based polygenic score links depression-related corticolimbic gene expression changes to sex-specific brain morphology and depression risk. Neuropsychopharmacology, 2021, 46, 2304-2311.	2.8	5
261	Use of Socioeconomic Status in Health Research. JAMA - Journal of the American Medical Association, 2006, 295, 1770.	3.8	4
262	Reverse translation of major depressive disorder symptoms: A framework for the behavioural phenotyping of putative biomarkers. Journal of Affective Disorders, 2020, 263, 353-366.	2.0	4
263	The association between genetically determined ABO blood types and major depressive disorder. Psychiatry Research, 2021, 299, 113837.	1.7	4
264	Replication of machine learning methods to predict treatment outcome with antidepressant medications in patients with major depressive disorder from STAR*D and CAN-BIND-1. PLoS ONE, 2021, 16, e0253023.	1.1	4
265	Hallucinations during lamotrigine treatment of bipolar disorder. American Journal of Psychiatry, 2006, 163, 749-50.	4.0	4
266	The Text4HealthyAging Program: An Evidence-Based Text Messaging Innovation to Support Healthy Urban Aging in Canada and Australia. Gerontology and Geriatric Medicine, 2022, 8, 233372142210813.	0.8	4
267	The role of bipolar polygenic risk score in the familial transmission of bipolar disorder—An updated analysis. Bipolar Disorders, 2022, 24, 437-440.	1.1	4
268	The Changing Understanding of the Genetic and Environmental Causes of Mental Illness. Canadian Journal of Psychiatry, 2013, 58, 67-68.	0.9	3
269	Association of a Brain Methylation Site With Clinical Outcomes in Depression Does Not Replicate Across Populations. American Journal of Psychiatry, 2015, 172, 395-397.	4.0	3
270	Youth Experience Tracker Instrument: A selfâ€report measure of developmental antecedents to severe mental illness. Microbial Biotechnology, 2021, 15, 676-685.	0.9	3

#	Article	IF	CITATIONS
271	Treatment-emergent and trajectory-based peripheral gene expression markers of antidepressant response. Translational Psychiatry, 2021, 11, 439.	2.4	3
272	Dimensions of temperament and character as predictors of antidepressant discontinuation, response and adverse reactions during treatment with nortriptyline and escitalopram. Psychological Medicine, 2021, , 1-9.	2.7	3
273	Common Data Elements to Facilitate Sharing and Re-use of Participant-Level Data: Assessment of Psychiatric Comorbidity Across Brain Disorders. Frontiers in Psychiatry, 2022, 13, 816465.	1.3	3
274	T38GENETIC COUNSELLING FOR THE PREVENTION OF MENTAL HEALTH CONSEQUENCES OF CANNABIS USE: A RANDOMIZED CONTROLLED TRIAL. European Neuropsychopharmacology, 2019, 29, S237.	0.3	2
275	Visual memory in offspring of parents with mental illness. Psychiatry Research, 2020, 286, 112813.	1.7	2
276	Managing patients' information in a community mental health team. Psychiatric Bulletin, 2006, 30, 172-174.	0.3	1
277	Antidepressant effects of nortriptyline and escitalopram in the <scp>GENDEP</scp> study: Is one better than the other?. Acta Psychiatrica Scandinavica, 2013, 127, 330-330.	2.2	1
278	Decision-making and $\hat{a} \in \mathbb{Z}$ gut feeling $\hat{a} \in \mathbb{Z}$ in males with anorexia nervosa. Advances in Eating Disorders (Abingdon, England), 2013, 1, 51-60.	0.8	1
279	Response to Kunte et al American Journal of Psychiatry, 2015, 172, 201-201.	4.0	1
280	785. Structural Properties and Connectivity of the Right Inferior Frontal Gyrus in Individuals at Genetic Risk for Bipolar Disorders. Biological Psychiatry, 2017, 81, S319.	0.7	1
281	Adversity, Parental Mental Illness, and Risk of Depression in Youth. European Psychiatry, 2017, 41, S220-S220.	0.1	1
282	Psychological interventions in offspring of parents with bipolar disorder. , 2018, , 247-264.		1
283	No Association Between Antidepressant Efficacy and rs28365143 in Corticotropin-Releasing Hormone Binding Protein in a Large Meta-Analysis. American Journal of Psychiatry, 2018, 175, 575-576.	4.0	1
284	Active behaviors and screen time in offspring of parents with major depressive disorder, bipolar disorder and schizophrenia. Psychiatry Research, 2020, 285, 112709.	1.7	1
285	Genetic counselling for the prevention of mental health consequences of cannabis use: A randomized controlled trialâ€withinâ€cohort. Microbial Biotechnology, 2020, 15, 1306-1314.	0.9	1
286	Pre-Treatment Resting-State Functional Connectivity Related to Anhedonia and Anxiety are Associated With Antidepressant Response to Escitalopram and Adjunct Aripiprazole. Biological Psychiatry, 2020, 87, S431.	0.7	1
287	Diagnoses. Mental Health and Illness Worldwide, 2020, , 3-15.	0.1	1
288	Visual memory and psychotic symptoms in youth. Cognitive Neuropsychiatry, 2020, 25, 231-241.	0.7	1

#	Article	IF	Citations
289	Interactions between neuroticism and stressful life events predict response to pharmacotherapy for major depression: A CANâ€BIND 1 report. Personality and Mental Health, 2021, 15, 273-282.	0.6	1
290	Parental Overprotection and Sleep Problems in Young Children. Child Psychiatry and Human Development, 2021, , 1.	1.1	1
291	Metabolic variables associated with response to cognitive behavioural therapy for depression in females: A Canadian biomarker integration network for depression (CAN-BIND) study. Journal of Psychiatric Research, 2021, 142, 321-327.	1.5	1
292	Neuroimaging and Eating Disorders. , 2003, , 171-190.		1
293	Dr Uher and Colleagues Reply. Journal of Clinical Psychiatry, 2020, 82, .	1.1	1
294	P.3.13 Temperament and character of subjects with treatment increase suicidal ideations in the GENDEP study. European Neuropsychopharmacology, 2009, 19, S72-S73.	0.3	0
295	Are children of depressed mothers exposed to higher contextual, family and mother-based risks?. European Psychiatry, 2011, 26, 1193-1193.	0.1	0
296	P.4.015 Gene expression profile associated with major depression and with antidepressant response. European Neuropsychopharmacology, 2012, 22, S95-S96.	0.3	0
297	P.4.002 Genetic differences in drug-metabolising enzymes: can they be used to predict antidepressant treatment response?. European Neuropsychopharmacology, 2013, 23, S69-S70.	0.3	0
298	Rating Short-Term Psychodynamic Therapy for the Canadian Network for Mood and Anxiety Treatments Depression Guidelines. Canadian Journal of Psychiatry, 2017, 62, 77-78.	0.9	0
299	New Insights Into The Pharmacogenomics Of Antidepressant Response From The Gendep And Star*D Studies: Results Of Rare Variant Analysis And High-Density Imputation. European Neuropsychopharmacology, 2017, 27, S443-S444.	0.3	0
300	255. Greater Gyrification of the Inferior Frontal Gyrus as a Marker of Genetic Risk for Bipolar Disorders. Biological Psychiatry, 2017, 81, S105.	0.7	0
301	Meta-analysis of CYP2C19 association with efficacy and side effects of citalopram and escitalopram. European Neuropsychopharmacology, 2017, 27, S582-S583.	0.3	0
302	T233. Obesity and Brain Age in First Episode of Schizophrenia-Spectrum Disorders – Effects of Antipsychotic Medications. Biological Psychiatry, 2018, 83, S219.	0.7	0
303	T75GWAS AND PATHWAY ENRICHMENT ANALYSIS IN ADVERSE DRUG REACTIONS IN DEPRESSION. European Neuropsychopharmacology, 2019, 29, S255-S256.	0.3	0
304	META-ANALYSIS OF CYP2C19 ASSOCIATION WITH EFFICACY AND SIDE EFFECTS OF CITALOPRAM AND ESCITALOPRAM USING DATA FROM GENOME-WIDE ASSOCIATION STUDIES. European Neuropsychopharmacology, 2019, 29, S808.	0.3	0
305	F52. WHO CO-PARENT CHILDREN WITH MOTHERS AND FATHERS WITH SCHIZOPHRENIA OR BIPOLAR DISORDER? CHARACTERIZING INDIVIDUALS WHO HAVE CHILDREN TOGETHER WITH INDIVIDUALS WITH SCHIZOPHRENIA OR BIPOLAR DISORDER. Schizophrenia Bulletin, 2019, 45, S275-S275.	2.3	0
306	F107. Cortical Thickness Features Differentiate 16-Week Antidepressant Response Profiles in Major Depressive Disorder. Biological Psychiatry, 2019, 85, S254.	0.7	0

#	Article	IF	CITATIONS
307	S124. Impact of CYP2C19 and CYP2D6 Genotypes on Clinical Outcomes and Side Effects in Patients Receiving Escitalopram and Aripiprazole for Major Depression: Results From the Can-Bind Cohort. Biological Psychiatry, 2019, 85, S344-S345.	0.7	0
308	M31 IMPACT OF CYP2C19 AND CYP2D6 GENE VARIANTS ON PLASMA LEVELS AND TREATMENT RESPONSE IN PATIENTS RECEIVING ESCITALOPRAM AND ARIPIPRAZOLE FOR MAJOR DEPRESSION: RESULTS FROM THE CAN-BIND-1 COHORT. European Neuropsychopharmacology, 2019, 29, S183.	0.3	0
309	T2. Brain Age in Bipolar Disorders - Effects of Lithium Treatment. Biological Psychiatry, 2019, 85, S130.	0.7	0
310	INTERGENERATIONAL TRANSMISSION OF PSYCHOPATHOLOGY AND EARLY IDENTIFICATION OF RISK: NEW INSIGHTS FROM THE STUDY OF CHILD AND ADOLESCENT OFFSPRING OF PARENTS LIVING WITH DEPRESSION, BIPOLAR DISORDER, AND SCHIZOPHRENIA. Journal of the American Academy of Child and Adolescent Psychiatry, 2020, 59, S305.	0.3	0
311	26.4 EARLY TRANSDIAGNOSTIC IDENTIFICATION OF RISK FOR MAJOR MOOD AND PSYCHOTIC DISORDERS. Journal of the American Academy of Child and Adolescent Psychiatry, 2020, 59, S306.	0.3	O
312	Early Identification of Risk for Major Depressive Disorder in the FORBOW Project. Biological Psychiatry, 2020, 87, S5.	0.7	0
313	Diagnoses. Mental Health and Illness Worldwide, 2020, , 1-13.	0.1	0
314	Response Inhibition and Predicting Response to Pharmacological and Cognitive Behavioral Therapy Treatments for Major Depressive Disorder: A Canadian Biomarker Integration Network for Depression Study. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2023, 8, 162-170.	1.1	0